• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SNDL Reports Third Quarter 2025 Financial and Operational Results

    11/4/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email

    EDMONTON, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the third quarter ended September 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

    SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com.

    The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, November 4, 2025. The conference call details can be found below.

    MANAGEMENT HIGHLIGHTS

    • Net revenue: In the third quarter of 2025, net revenue totaled $244.2 million, reflecting a growth rate of +3.1% compared to the same period in the previous year. This increase was primarily driven by strong growth of +13.5% in our combined Cannabis business, partly offset by Liquor retail segment decline.
    • Gross profit: Gross profit for the third quarter of 2025 reached $64.2 million, representing a +1.9% increase compared to the same period in the prior year.
    • Gross margin (1): The gross margin in the third quarter of 2025 was 26.3%, reflecting a year-over-year decrease of -0.3 percentage points. Strong margin expansion in Liquor Retail (+0.8pp) and Cannabis Retail segments (+0.9pp) was more than offset by non-cash inventory adjustments in the Cannabis Operations segment, which had a -10.4pp impact to segment margin and -1.6pp to consolidated margin.
    • Operating Income: The Company reported an operating loss of $(11.1) million in the third quarter of 2025. This result was impacted by a $(6.8) million non-cash increase in share-based compensation liability reflected in the Corporate segment, due to the mark-to-market impact of the Company's 121% share price increase during the quarter, a $(3.9) million non-cash inventory-related adjustments within Cannabis Operations, and a $(1.6) million net fixed asset write-off, mostly related to the idle Stellarton facility. It also includes a $(1.5) million restructuring charge, resulting in an adjusted operating loss of $(9.5) million. Both reported and adjusted operating loss exclude a $5.3 million realized gain from the partial sale of some of our equity investments.
    • Cash flow: Cash flow was $32.4 million during the third quarter of 2025, primarily driven by $15.1 million in proceeds from the disposal of certain equity investments, and a $14.3 million reduction in working capital following seasonal increases in the first half of the year.
    • Free cash flow (1): Free cash flow in the third quarter of 2025 reached a record $16.7 million, primarily driven by a reduction in working capital. This result reflects $5.2 million CAPEX investments ahead of new Liquor and Cannabis Retail store openings scheduled for the fourth quarter. The income statement also contributed to the record free cash flow, as the operating loss was largely attributable to non-cash items. Note that proceeds of $15.1 million from the disposal of certain equity investments are not included in the free cash flow for the quarter.



    "Reaching a new record for quarterly free cash flow and, for the first time in our history, achieving positive cumulative free cash flow for the first nine months of the year underscores the strength of our ongoing operational and profitability improvements," said Zach George, Chief Executive Officer of SNDL. "We are delivering these results while continuing to grow our Cannabis business well ahead of market and industry peers and accelerating the pace of organic growth investments.

    Unlike many players in the industry, SNDL reports its financial performance using rigorous, unadjusted KPIs. Leadership in our industry begins with financial integrity and transparency, principles we owe to our shareholders and ourselves.

    Our relentless focus on growth and value creation is reflected not only in our financial progress but also in the strategic decisions that position SNDL for long-term success."

    The Company's strong balance sheet, with no debt and $240.6 million in unrestricted cash as of September 30, 2025, provides a strategic advantage as we continue building a resilient, growth-oriented, and profitable business. This financial strength enables us to pursue several high-return organic and inorganic opportunities without issuing equity or incurring high interest debt. Examples of these opportunities include:

    • Acquisition of 1CM Retail Stores: SNDL previously announced an arrangement agreement to acquire 32 cannabis retail stores from 1CM Inc. ("1CM") for a total cash consideration of $32.2 million. We continue to support the regulatory review process in Ontario, the final step before closing the transaction.
    • Strategic Organic Investments: Targeted CAPEX and working capital investments in support of five additional Cannabis store openings and two new Wine & Beyond stores expected during the fourth quarter.
    • Atholville Facility Ramp: Completion of the capacity ramp-up of our Atholville cultivation facility, which combined with strong commercial relationships, enabled us to achieve $4.2 million in international sales during the third quarter.
    • Equity Monetization: Partial sale of SNDL's equity position in High Tide Inc. ("High Tide"), realizing a gain of $5.3 million during the third quarter.
    • SunStream Restructuring Process: The Company continues to work toward the resolution of on-going litigation required to complete SunStream Bancorp Inc. ("SunStream") restructurings. Once completed, these restructurings are expected to provide shareholders with exposure to dynamic medical cannabis markets including Florida and Texas.



    "In a rapidly evolving market, our agility and resilience remain key strengths as we pursue our ambition to become a global cannabis leader. Our team is the foundation of our success, and we are confident in our ability to deliver on our goals." concluded Zach George.

    TOTAL COMPANY HIGHLIGHTS

     Three months ended September 30 Nine months ended September 30 
    ($000s)2025 2024 % Change 2025 2024 % Change 
    IFRS Financial Measures            
    Net revenue 244,219  236,892  3.1% 693,902  662,769  4.7%
    Gross profit 64,177  62,968  1.9% 188,419  171,532  9.8%
    Operating income (loss) (11,050) (18,511) 40.3% (18,100) (27,722) 34.7%
    Change in cash and cash equivalents 32,357  80,042  -59.6% 22,222  67,935  -67.3%
                 
    Non-IFRS Financial Measures(1)            
    Gross margin 26.3% 26.6% -0.3pp 27.2% 25.9% 1.3pp
    Adjusted operating income (loss) (9,512) (16,593) 42.7% (12,713) (25,672) 50%
    Free cash flow 16,692  9,236  80.7% 7,733  (2,753) 381%

    (1)   Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have a standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures reported by other companies. See "Non-IFRS Measures" section below for further information.

    BUSINESS SEGMENT HIGHLIGHTS

    SNDL operates and reports its business through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Additionally, a consolidated total for Cannabis is presented, encompassing the combined results of the two Cannabis segments, along with the revenue elimination associated with the Cannabis Operations sales to the provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale. Corporate and Shared Service expenses are reported as "Corporate".

     Three months ended September 30 Nine months ended September 30 
    ($000s)2025 2024 % Change 2025 2024 % Change 
    Net Revenue            
    Cannabis Retail 85,021  81,144  4.8% 246,960  228,519  8.1%
    Cannabis Operations 37,389  25,007  49.5% 107,544  72,378  48.6%
    Intersegment Eliminations (17,579) (13,824) -27.2% (51,391) (39,307) -30.7%
    Total Cannabis 104,831  92,327  13.5% 303,113  261,590  15.9%
    Liquor Retail 139,388  144,565  -3.6% 390,789  401,179  -2.6%
    Investments —  —  0.0% —  —  0.0%
    Total 244,219  236,892  3.1% 693,902  662,769  4.7%
                 
    Operating Income            
    Cannabis Retail 9,105  4,395  107.2% 22,329  7,255  207.8%
    Cannabis Operations (5,434) (703) -673.0% (3,628) (1,728) -110.0%
    Total Cannabis 3,671  3,692  -0.6% 18,701  5,527  238.4%
    Liquor Retail 11,222  11,795  -4.9% 24,276  22,456  8.1%
    Investments 1,543  (7,824) 119.7% 1,775  13,711  -87.1%
    Corporate (27,486) (26,174) -5.0% (62,852) (69,416) 9.5%
    Total (11,050) (18,511) 40.3% (18,100) (27,722) 34.7%
                 
    Adjusted Operating Income            
    Cannabis Retail 9,105  4,395  107.2% 22,329  7,255  207.8%
    Cannabis Operations (4,772) (578) -725.6% 300  (1,348) 122.3%
    Total Cannabis 4,333  3,817  13.5% 22,629  5,907  283.1%
    Liquor Retail 11,222  11,795  -4.9% 24,276  22,456  8.1%
    Investments 1,543  (7,824) 119.7% 1,775  13,711  -87.1%
    Corporate (26,610) (24,381) -9.1% (61,393) (67,746) 9.4%
    Total (9,512) (16,593) 42.7% (12,713) (25,672) 50.5%



    Liquor Retail

    SNDL is Canada's largest private sector liquor retailer, operating at November 3, 2025 in 165 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond" (13), "Liquor Depot" (19), and "Ace Liquor" (133).

     Three months ended September 30 Nine months ended September 30 
    ($000s)2025 2024 % Change 2025 2024 % Change 
    Net revenue 139,388  144,565  -3.6% 390,789  401,179  -2.6%
    Gross profit 36,704  36,951  -0.7% 100,993  101,470  -0.5%
    Gross margin 26.3% 25.6% 0.8pp 25.8% 25.3% 0.6pp
    Operating income 11,222  11,795  -4.9% 24,276  22,456  8.1%
    Adjusted operating income 11,222  11,795  -4.9% 24,276  22,456  8.1%
                       
    • Net revenue for Liquor Retail declined in the third quarter of 2025, driven by continued softness in market demand. Same-store sales (2) decreased by -2.6% due to industry-wide volume declines primarily affecting our convenience banners (Ace Liquor and Liquor Depot). In contrast, our Wine & Beyond banner demonstrates resilience, achieving same store sales growth of 2.9% during the quarter.



    (2)   Same store sales is a specified financial measure that does not have a standardized meaning prescribed by IFRS Accounting Standards and therefore may not be comparable to similar measures used by other companies. See "Non-IFRS Financial Measures" section below for further information.

    • During the third quarter of 2025, the gross margin for Liquor Retail continued to improve compared to the previous year, marking another record high for the segment. Operating Income showed a slight decline, as the benefits of gross margin expansion and further SG&A cost efficiencies were more than offset by the lapping of a $1.2 million favorable fixed asset revaluation recorded in the same period last year.



    Cannabis Retail

    SNDL is one of Canada's largest private-sector cannabis retailer, operating at November 3, 2025 in 186 locations under its two retail banners: "Value Buds" (125), and "Spiritleaf" (61, of which 4 are corporate stores and 57 are franchise stores). The Company's Cannabis Retail strategy is based on several pillars, including the quality of its store locations, its range of products, and the unique experiences provided to customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

     Three months ended September 30 Nine months ended September 30 
    ($000s)2025 2024 % Change 2025 2024 % Change 
    Net revenue 85,021  81,144  4.8% 246,960  228,519  8.1%
    Gross profit 22,465  20,710  8.5% 63,974  58,337  9.7%
    Gross margin 26.4% 25.5% 0.9pp 25.9% 25.5% 0.4pp
    Operating income 9,105  4,395  107.2% 22,329  7,255  207.8%
    Adjusted operating income 9,105  4,395  107.2% 22,329  7,255  207.8%
                       
    • The Cannabis Retail segment achieved three new quarterly records: Net Revenue, Gross Profit and Operating Income.
    • Year-over-year Net Revenue growth in the third quarter was supported by a 3.6% increase in same-store sales. The slowdown in revenue growth compared to previous quarters was primarily due to the lapping of heavier promotional periods during the second half of 2024. This reduction in promotional intensity was the main driver of gross margin improvement.
    • Operating Income experienced substantial growth, driven by higher revenue and gross margin, as well as productivity initiatives lowering SG&A. Additionally, in the third quarter of 2025 there was a $1.0 million reversal of fixed asset impairments recorded several years ago, reflecting continued improvement in store performance.



    Cannabis Operations

    SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy.

     Three months ended September 30 Nine months ended September 30 
    ($000s)2025 2024 % Change 2025 2024 % Change 
    Net revenue 37,389  25,007  49.5% 107,544  72,378  48.6%
    Gross profit 5,008  5,307  -5.6% 23,452  11,725  100.0%
    Gross margin 13.4% 21.2% -7.8pp 21.8% 16.2% 5.6pp
    Operating income (loss) (5,434) (703) -673.0% (3,628) (1,728) -110.0%
    Adjusted operating income (loss) (4,772) (578) -725.6% 300  (1,348) 122.3%
                       
    • Cannabis Operations continued to deliver significant revenue growth in the third quarter of 2025, reaching a new net revenue record for the segment.
    • Growth was driven by edibles, following Indiva's acquisition in the fourth quarter of 2024, as well as accelerating international sales, which reached $4.2 million during the quarter.
    • Gross profit and Operating Income were impacted by inventory write-offs and valuation adjustments, primarily related to the cultivation ramp-up, and the fixed asset write-off of the idle Stellarton facility.



    Investments

    • As of September 30, 2025, the Company has deployed capital to a portfolio of cannabis-related investments with a carrying value of $410.8 million, including $391.1 million to SunStream. This carrying value increased by $4.7 million during the third quarter of 2025, primarily due to an increase in the USD to CAD exchange rate from 1.3643 on June 30, 2025 to 1.3921 on September 30, 2025.
    • During the third quarter of 2025, the investment portfolio generated a positive operating income of $1.5 million, primarily driven by interests earned from our cash accounts.
    • In the third quarter of 2025, the Company sold 2,929,371 common shares of High Tide, reducing its holdings to 3,693,274 shares as of September 30, 2025, representing 4.2% ownership. In October 2025, the Company disposed of an additional 599,758 common shares, bringing its total position down to 3,093,516 shares by November 3, 2025, or 3.6% ownership. To date, these dispositions have resulted in a realized gain of $6.3 million, comprising $5.3 million recognized in the third quarter and the remaining $1.0 million in October 2025. The Company recorded these gains as part of other comprehensive income, below the Net Income/(Loss) line.



    Equity Position

    • $651.5 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees, and no outstanding debt at September 30, 2025, resulting in a net book value of $1.1 billion.
    • The board of directors of the Company has approved the renewal of its Share Repurchase Program upon the expiry of its current share repurchase program on November 20, 2025. The Share Repurchase Program remains subject to the filing of the required notice with, and acceptance by, the Canadian Securities Exchange.
    • For the three months ended September 30, 2025, the Company purchased and cancelled 1,800 common shares at a weighted average price of US$1.21 per share. SNDL will continue to evaluate opportunities to utilize the program to the extent that management believes it is in the best interest of SNDL's shareholders. As a reminder, since the fourth quarter of 2024 the Company repurchased 10,765,907 common shares for cancellation.



    This press release is intended to be read in conjunction with the Company's condensed consolidated interim financial statements and the notes thereto for the three and nine months ended September 30, 2025, and the accompanying Management's Discussion and Analysis. These documents are available under the Company's profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml. 

    CONFERENCE CALL  

    The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, November 4, 2025.

    WEBCAST ACCESS

    To access the live webcast of the call, please visit the following link:

    https://edge.media-server.com/mmc/p/gutfgczk

    REPLAY

    A replay of the webcast will be available at https://sndl.com/financials/quarterly-results/default.aspx

    ABOUT SNDL INC. 

    SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds and Spiritleaf. With products available in licensed cannabis retail locations nationally, SNDL's consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com 

    For more information: 

    Tomas Bottger

    SNDL Inc. 

    O: 1.587.327.2017 

    E: [email protected]

    Forward-Looking Information Cautionary Statement    

    This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals and plans, the benefits of SNDL's financial reporting compared to industry peers, the Company's ability to achieve long-term, sustainable profitability, growth, success and efficiencies, the anticipated benefit of the Company's strong balance sheet, the growth opportunities available to SNDL and the expected benefits thereof, the timing and closing of the transaction to acquire assets from 1CM, the expected benefits of the Sunstream restructurings, the treatment of Cannabis Operations sales to the provincial boards, the Company's retail strategy, expectations with respect to the Company's Cannabis Operations segment, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as "aim", "anticipate", "assume", "believe", "contemplate", "continue", "could", "due", "estimate", "expect", "goal", "intend", "may", "objective", "plan", "predict", "potential", "positioned", "pioneer", "seek", "should", "target", "will", "would", and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company's business and the industry in which it operates and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Risk Factors" in the Company's Annual Information Form dated March 18, 2025, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.   



     
    Condensed Consolidated Interim Statement of Loss and Comprehensive Loss

    (Expressed in thousands of Canadian dollars, except per share amounts)
     
      Three months ended

    September 30
      Nine months ended

    September 30
     
      2025  2024  2025  2024 
    Net revenue  244,219   236,892   693,902   662,769 
    Cost of sales  180,042   173,924   505,483   491,237 
    Gross profit  64,177   62,968   188,419   171,532 
                 
    Investment income  1,777   5,577   6,162   12,817 
    Share of (loss) profit of equity-accounted investees  (234)  (13,401)  (4,387)  999 
                 
    General and administrative  45,967   49,980   137,702   142,711 
    Sales and marketing  3,617   2,813   10,768   8,850 
    Depreciation and amortization  12,928   13,389   39,076   41,051 
    Share-based compensation  10,883   5,702   15,190   15,428 
    Restructuring costs  1,134   1,918   2,287   2,050 
    Asset impairment (recovery), net  2,051   (258)  2,971   2,317 
    Research and development  156   76   354   222 
    Loss (gain) on disposition of assets  34   35   (54)  441 
    Operating loss  (11,050)  (18,511)  (18,100)  (27,722)
                 
    Other (expenses) income, net  (2,269)  609   (7,041)  (4,080)
    Loss before income tax  (13,319)  (17,902)  (25,141)  (31,802)
    Income tax (expense) recovery  —   (1,434)  —   2,847 
    Net loss  (13,319)  (19,336)  (25,141)  (28,955)
                 
    Equity-accounted investees - share of other comprehensive income (loss)  7,709   (4,802)  (13,250)  9,532 
    Investments at fair value through other comprehensive income ("FVOCI") - change in fair value  12,940   —   9,754   — 
    Comprehensive income (loss)  7,330   (24,138)  (28,637)  (19,423)
                 
    Net loss attributable to:            
    Owners of the Company  (13,319)  (19,328)  (25,141)  (27,654)
    Non-controlling interest  —   (8)  —   (1,301)
       (13,319)  (19,336)  (25,141)  (28,955)
    Comprehensive income (loss) attributable to:            
    Owners of the Company  7,330   (24,130)  (28,637)  (18,122)
    Non-controlling interest  —   (8)  —   (1,301)
       7,330   (24,138)  (28,637)  (19,423)
    Net loss per common share attributable to owners of the Company            
    Basic and diluted $(0.05) $(0.07) $(0.10) $(0.10)



     
    Condensed Consolidated Interim Statement of Financial Position

    (Expressed in thousands of Canadian dollars)

     
    As atSeptember 30, 2025 December 31, 2024 
         
    Assets    
    Current assets    
    Cash and cash equivalents 240,581  218,359 
    Restricted cash 19,798  19,815 
    Marketable securities 139  139 
    Accounts receivable 26,299  28,118 
    Biological assets 3,507  1,187 
    Inventory 125,334  127,919 
    Prepaid expenses and deposits 12,580  16,860 
    Investments 595  27,560 
    Assets held for sale 746  19,051 
    Net investment in subleases 2,754  2,832 
      432,333  461,840 
    Non-current assets    
    Long-term deposits and receivables 4,460  3,679 
    Right of use assets 122,701  115,435 
    Property, plant and equipment 152,510  145,810 
    Net investment in subleases 12,350  15,354 
    Intangible assets 59,224  61,325 
    Investments 19,089  8,427 
    Equity-accounted investees 391,146  413,124 
    Goodwill 124,248  124,248 
    Total assets 1,318,061  1,349,242 
         
    Liabilities    
    Current liabilities    
    Accounts payable and accrued liabilities 50,652  56,275 
    Lease liabilities 35,158  34,256 
    Derivative warrants —  26 
      85,810  90,557 
    Non-current liabilities    
    Lease liabilities 119,971  118,017 
    Other liabilities 12,989  7,312 
    Total liabilities 218,770  215,886 
         
    Shareholders' equity    
    Share capital 2,295,625  2,346,728 
    Warrants 667  667 
    Contributed surplus 66,435  57,156 
    Accumulated deficit (1,312,710) (1,323,965)
    Accumulated other comprehensive income ("AOCI") 49,274  52,770 
    Total shareholders' equity 1,099,291  1,133,356 
    Total liabilities and shareholders' equity 1,318,061  1,349,242 



     
    Condensed Consolidated Interim Statement of Cash Flows

    (Expressed in thousands of Canadian dollars)
     
      Three months ended

    September 30
      Nine months ended

    September 30
     
      2025  2024  2025  2024 
    Cash provided by (used in):            
    Operating activities            
    Net loss for the period  (13,319)  (19,336)  (25,141)  (28,955)
    Adjustments for:            
    Income tax expense (recovery)  —   1,434   —   (2,847)
    Interest and fee income  (1,675)  (5,577)  (5,849)  (12,886)
    Change in fair value of biological assets  (784)  167   (2,559)  (401)
    Change in fair value of inventory sold  1,313   —   1,313   — 
    Share-based compensation  10,883   5,702   15,190   15,428 
    Depreciation and amortization  13,972   13,970   42,108   42,679 
    Loss (gain) on disposition of assets  34   35   (54)  441 
    Inventory impairment and obsolescence  1,833   413   2,663   3,395 
    Finance costs, net  1,812   1,740   5,149   5,522 
    Change in estimate of fair value of derivative warrants  (1)  (3,848)  (26)  (4,348)
    Unrealized foreign exchange (gain) loss  (153)  80   40   235 
    Transaction costs  —   —   —   164 
    Asset impairment (recovery), net  2,051   (258)  2,971   2,317 
    Share of loss (profit) of equity-accounted investees  234   13,401   4,387   (999)
    Unrealized (gain) loss on marketable securities  (102)  —   (313)  69 
    Additions to marketable securities  —   (327)  313   (327)
    Income distributions from equity-accounted investees  —   10,715   68   10,715 
    Interest received  1,409   4,496   5,628   10,317 
    Change in non-cash working capital  14,194   (13)  (282)  (9,722)
    Net cash provided by operating activities  31,701   22,794   45,606   30,797 
    Investing activities            
    Additions to property, plant and equipment  (5,185)  (1,706)  (8,853)  (5,306)
    Additions to intangible assets  —   (2,421)  —   (2,421)
    Additions to investments  —   (29,066)  (16,414)  (29,966)
    Principal payments from investments  129   10,114   27,293   12,382 
    Proceeds from disposal of investments  15,058   —   15,058   — 
    Capital refunds from equity-accounted investees  —   —   —   168 
    Capital distributions from equity-accounted investees  481   89,758   4,273   89,758 
    Proceeds from disposal of property, plant and equipment  —   —   166   126 
    Acquisitions, net of cash acquired  —   —   (1,000)  (1,654)
    Change in non-cash working capital  39   (191)  10   379 
    Net cash provided by investing activities  10,522   66,488   20,533   63,466 
    Financing activities            
    Change in restricted cash  —   (243)  —   (324)
    Payments on lease liabilities, net  (9,920)  (9,780)  (29,217)  (27,002)
    Repurchase of common shares  (3)  —   (15,034)  — 
    Proceeds from issuance of shares, net of costs  —   —   —   (57)
    Issuance of common shares by subsidiaries  —   —   —   174 
    Change in non-cash working capital  57   783   334   881 
    Net cash used in financing activities  (9,866)  (9,240)  (43,917)  (26,328)
    Change in cash and cash equivalents  32,357   80,042   22,222   67,935 
    Cash and cash equivalents, beginning of period  208,224   182,934   218,359   195,041 
    Cash and cash equivalents, end of period  240,581   262,976   240,581   262,976 



    NON-IFRS MEASURES

    Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team.  

    ADJUSTED OPERATING INCOME (LOSS)

    Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

    The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.

    ($000s)Cannabis

    Retail
     Cannabis

    Operations
     Cannabis

    Total
     Liquor

    Retail
     Investments Corporate Total 
    Three months ended September 30, 2025 
    Operating income (loss) 9,105  (5,434) 3,671  11,222  1,543  (27,486) (11,050)
    Adjustments:              
    Restructuring costs —  258  258  —  —  876  1,134 
    Impairments triggered by restructuring —  404  404  —  —  —  404 
    Adjusted operating income (loss) 9,105  (4,772) 4,333  11,222  1,543  (26,610) (9,512)



    ($000s)Cannabis

    Retail
     Cannabis

    Operations
     Cannabis

    Total
     Liquor

    Retail
     Investments Corporate Total 
    Nine months ended September 30, 2025 
    Operating income (loss) 22,329  (3,628) 18,701  24,276  1,775  (62,852) (18,100)
    Adjustments:              
    Restructuring costs —  828  828  —  —  1,459  2,287 
    Impairments triggered by restructuring —  3,100  3,100  —  —  —  3,100 
    Adjusted operating income (loss) 22,329  300  22,629  24,276  1,775  (61,393) (12,713)



    ($000s)Cannabis

    Retail
     Cannabis

    Operations
     Cannabis

    Total
     Liquor

    Retail
     Investments Corporate Total 
    Three months ended September 30, 2024 
    Operating income (loss) 4,395  (703) 3,692  11,795  (7,824) (26,174) (18,511)
    Adjustments:              
    Restructuring costs —  125  125  —  —  1,793  1,918 
    Adjusted operating income (loss) 4,395  (578) 3,817  11,795  (7,824) (24,381) (16,593)



    ($000s)Cannabis

    Retail
     Cannabis

    Operations
     Cannabis

    Total
     Liquor

    Retail
     Investments Corporate Total 
    Nine months ended September 30, 2024 
    Operating income (loss) 7,255  (1,728) 5,527  22,456  13,711  (69,416) (27,722)
    Adjustments:              
    Restructuring costs —  380  380  —  —  1,670  2,050 
    Adjusted operating income (loss) 7,255  (1,348) 5,907  22,456  13,711  (67,746) (25,672)



    GROSS MARGIN


    Gross margin is a supplementary financial measure calculated by dividing gross profit by net revenue for the periods noted.

    FREE CASH FLOW 

    Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company's ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).

    The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.

      Three months ended

    September 30
      Nine months ended

    September 30
     
    ($000s) 2025  2024  2025  2024 
    Change in cash and cash equivalents  32,357   80,042   22,222   67,935 
    Adjustments:            
    Repurchase of common shares  3   —   15,034   — 
    Changes to long-term investments  (15,668)  (70,806)  (30,523)  (72,342)
    Acquisitions, net of cash acquired  —   —   1,000   1,654 
    Free cash flow  16,692   9,236   7,733   (2,753)



    SAME STORE SALES


    Same store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company's sales trends excluding the effect of the opening and closure of stores.

    Same store sales refers to the revenue generated by the Company's existing retail locations during the current and prior comparison periods.



    Primary Logo

    Get the next $SNDL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDL

    DatePrice TargetRatingAnalyst
    9/3/2025$5.00Buy
    Alliance Global Partners
    7/17/2024Speculative Buy
    Canaccord Genuity
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $SNDL
    SEC Filings

    View All

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    11/4/25 7:05:03 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    10/30/25 8:52:58 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    10/15/25 4:46:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on SNDL Inc. with a new price target

    Alliance Global Partners initiated coverage of SNDL Inc. with a rating of Buy and set a new price target of $5.00

    9/3/25 7:54:28 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity resumed coverage on SNDL Inc.

    Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

    7/17/24 12:19:57 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

    8/16/22 7:59:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL Reports Third Quarter 2025 Financial and Operational Results

    EDMONTON, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the third quarter ended September 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, November 4, 2025. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue: In the third quarter of 2025, net revenue totaled $24

    11/4/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Announce Third Quarter 2025 Financial Results on November 4, 2025

    EDMONTON, Alberta, Oct. 15, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its third quarter 2025 financial results for the period ended September 30, 2025, before market opens on Tuesday, November 4, 2025. Following the release of its third quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on November 4, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/gutfgczk ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabi

    10/15/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Financials

    Live finance-specific insights

    View All

    SNDL Reports Third Quarter 2025 Financial and Operational Results

    EDMONTON, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the third quarter ended September 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, November 4, 2025. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue: In the third quarter of 2025, net revenue totaled $24

    11/4/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Announce Third Quarter 2025 Financial Results on November 4, 2025

    EDMONTON, Alberta, Oct. 15, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its third quarter 2025 financial results for the period ended September 30, 2025, before market opens on Tuesday, November 4, 2025. Following the release of its third quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on November 4, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/gutfgczk ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabi

    10/15/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports Second Quarter 2025 Financial and Operational Results

    The Company Delivers Positive Operating Income EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the second quarter ended June 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, July 31,

    7/31/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    1/31/24 4:48:48 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Subject)

    2/14/23 5:28:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    2/13/23 4:06:09 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Leadership Updates

    Live Leadership Updates

    View All

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Appoints New Chief Information Officer and New President, Liquor Division

    CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

    11/21/24 6:02:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2024 Annual General Meeting Results

    CALGARY, AB, July 30, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual General Meeting (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at six (6); (ii) electing each of Gregory Mills, Zachary George, Lori Ell, Frank Krasovec, Bryan Pinney and Gregory Turnbull as directors of the Company for the ensuing year; and (iii) re-appointing Marcum LLP as the auditors of the Company for the ensu

    7/30/24 5:45:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care